New Insights into the Regulation of Chylomicron Production

Annual Review of Nutrition

Volumn 35, Issue 1, 2015, Pages 265-294

  Dash, Satya ^a,b   Xiao, Changting ^a,b   Morgantini, Cecilia ^a,b   Lewis, Gary F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apolipoprotein B 48; Atherosclerosis; Chylomicron; Diabetic dyslipidemia; Triglyceride rich lipoprotein

Indexed keywords

ACYLTRANSFERASE INHIBITOR; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CARBOHYDRATE; CHOLESTEROL; CHYLOMICRON; CHYLOMICRON REMNANT; EZETIMIBE; FATTY ACID; FATTY ACID BINDING PROTEIN; FIBRIC ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; NUTRACEUTICAL; RESVERATROL; TRIACYLGLYCEROL; CHOLESTEROL INTAKE; FAT INTAKE; HORMONE;

ABETALIPOPROTEINEMIA; ATHEROSCLEROSIS; BARIATRIC SURGERY; CARBOHYDRATE INTAKE; CHOLESTEROL INTAKE; CHOLESTEROL SYNTHESIS; CHYLOMICRONEMIA; CIRCADIAN RHYTHM; DIETARY FIBER; FAT INTAKE; FAT MASS; FATTY ACID BLOOD LEVEL; FATTY ACID TRANSPORT; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPOBETALIPOPROTEINEMIA; INSULIN RESISTANCE; INSULIN RESPONSE; INTESTINE FLORA; INTRACELLULAR TRANSPORT; LIPID ABSORPTION; LIPID STORAGE; LIPOGENESIS; MONOGENIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BLOOD LEVEL; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN INTAKE; PROTEIN SECRETION; REVIEW; RNA TRANSLATION; TRIACYLGLYCEROL BLOOD LEVEL; BIOSYNTHESIS; BLOOD; DIET; DIETARY SUPPLEMENT; GENETICS; HOMEOSTASIS; INTESTINE; INTESTINE ABSORPTION; LIPID METABOLISM; METABOLISM; NUTRITION; PHARMACOKINETICS; PHARMACOLOGY; PHYSIOLOGY;

ATHEROSCLEROSIS; CHOLESTEROL, DIETARY; CHYLOMICRONS; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 2; DIET; DIETARY FATS; DIETARY SUPPLEMENTS; GASTROINTESTINAL MICROBIOME; HOMEOSTASIS; HORMONES; HUMANS; INSULIN RESISTANCE; INTESTINAL ABSORPTION; INTESTINES; LIPID METABOLISM; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; TRIGLYCERIDES;

EID: 84937548070     PISSN: 01999885     EISSN: 15454312     Source Type: Book Series    
DOI: 10.1146/annurev-nutr-071714-034338     Document Type: Review

References (178)

1. Aalto-Setala K, Bisgaier CL, Ho A, Kieft KA, Traber MG, et al. 1994. Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior. J. Clin. Invest. 93:1776-86
2. Agren JJ, Valve R, Vidgren H, Laakso M, Uusitupa M. 1998. Postprandial lipemic response is modified by the polymorphism at codon 54 of the fatty acid-binding protein 2 gene. Arterioscler. Thromb. Vasc. Biol. 18:1606-10
3. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, et al. 2004. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201-4
4. Amaro A, Fabbrini E, Kars M, Yue P, Schechtman K, et al. 2010. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 139:149-53
5. Anant S, Davidson NO. 2001. Molecular mechanisms of apolipoprotein B mRNA editing. Curr. Opin. Lipidol. 12:159-65
6. Baggio LL, Drucker DJ. 2007. Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-57
7. Baier LJ, Sacchettini JC, Knowler WC, Eads J, Paolisso G, et al. 1995. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J. Clin. Invest. 95:1281-87
8. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. 2007. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309-16
9. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337-42
10. Blackburn C, Guan B, Brown J, Cullis C, Condon SM, et al. 2006. Identification and characterization of 4-aryl-3,4-dihydropyrimidin-2(1H)-ones as inhibitors of the fatty acid transporter FATP4. Bioorg. Med. Chem. Lett. 16:3504-9
11. Botham KM,Moore EH, De Pascale C, Bejta F. 2007. The induction of macrophage foam cell formation by chylomicron remnants. Biochem. Soc. Trans. 35:454-58
12. Bozzetto L, Annuzzi G, Corte GD, Patti L, Cipriano P, et al. 2011. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 217:142-48
13. Brasnyo P,Molnar GA, MohasM,Marko L, Laczy B, et al. 2011. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106:383-89
14. Bray GA. 2012. Fructose and risk of cardiometabolic disease. Curr. Atheroscler. Rep. 14:570-78
15. Bruin T, Tuzgol S, van Diermen DE, Hoogerbrugge-van der Linden N, Brunzell JD, et al. 1993. Recurrent pancreatitis and chylomicronemia in an extended Dutch kindred is caused by a Gly154→Ser substitution in lipoprotein lipase. J. Lipid Res. 34:2109-19
16. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, et al. 2006. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116:1052-62
17. Buhman KK, Smith SJ, Stone SJ, Repa JJ, Wong JS, et al. 2002. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J. Biol. Chem. 277:25474-79
18. Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, et al. 2010. One-year treatment with exenatide versus insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 212:223-29
19. Cao J, Cheng L, Shi Y. 2007. Catalytic properties of MGAT3, a putative triacylglycerol synthase. J. Lipid Res. 48:583-91
20. Cara L, Dubois C, Borel P, Armand M, Senft M, et al. 1992. Effects of oat bran, rice bran, wheat fiber, and wheat germ on postprandial lipemia in healthy adults. Am. J. Clin. Nutr. 55:81-88
21. Cases S, Stone SJ, Zhou P, Yen E, Tow B, et al. 2001. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J. Biol. Chem. 276:38870-76
22. Chavez-Jauregui RN, Mattes RD, Parks EJ. 2010. Dynamics of fat absorption and effect of sham feeding on postprandial lipema. Gastroenterology 139:1538-48
23. Cheng D, Nelson TC, Chen J, Walker SG, Wardwell-Swanson J, et al. 2003. Identification of acyl coenzyme A:monoacylglycerol acyltransferase 3, an intestinal specific enzyme implicated in dietary fat absorption. J. Biol. Chem. 278:13611-14
24. Cohen JC, Berger GM. 1990. Effects of glucose ingestion on postprandial lipemia and triglyceride clearance in humans. J. Lipid Res. 31:597-602
25. Cohen JC, Stender S, Hobbs HH. 2014. APOC3, coronary disease, and complexities of Mendelian randomization. Cell Metab. 20:387-89
26. Cohn JS, Marcoux C, Davignon J. 1999. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler. Thromb. Vasc. Biol. 19:2474-86
27. Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, et al. 2014. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371:22-31
28. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, et al. 2007. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356:148-56
29. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, et al. 2013. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381:40-46
30. Dash S, Xiao C, Morgantini C, Connelly PW, Patterson BW, Lewis GF. 2014. Glucagon-like peptide 2 regulates release of chylomicron from the intestine. Gastroenterology 147:1275-84
31. Dash S, Xiao C, Morgantini C, Koulajian K, Lewis GF. 2015. Intranasal insulin suppresses endogenous glucose production in humans compared to placebo, in the presence of similar venous insulin concentration. Diabetes 64(3):766-74
32. Dash S, Xiao C, Morgantini C, Szeto L, Lewis GF. 2013. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler. Thromb. Vasc. Biol. 33:2895-901
33. Denison H, Nilsson C, Kujacic M, Lofgren L, Karlsson C, et al. 2013. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study. Diabetes Obes.Metab. 15:136-43
34. Desmarchelier C, Martin JC, Planells R, Gastaldi M, Nowicki M, et al. 2014. The postprandial chylomicron triacylglycerol response to dietary fat in healthy male adults is significantly explained by a combination of single nucleotide polymorphisms in genes involved in triacylglycerol metabolism. J. Clin. Endocrinol. Metab. 99:E484-88
35. Do R, Willer CJ, Schmidt EM, Sengupta S,Gao C, et al. 2013. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat. Genet. 45:1345-52
36. Douris N, Kojima S, Pan X, Lerch-Gaggl AF, Duong SQ, et al. 2011. Nocturnin regulates circadian trafficking of dietary lipid in intestinal enterocytes. Curr. Biol. 21:1347-55
37. Drucker DJ, Nauck MA. 2006. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-705
38. Drucker DJ, Yusta B. 2014. Physiology and pharmacology of the enteroendocrine hormone glucagonlike peptide-2. Annu. Rev. Physiol. 76:561-83
39. Dubois C, Beaumier G, Juhel C, Armand M, Portugal H, et al. 1998. Effects of graded amounts (0-50 g) of dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults. Am. J. Clin. Nutr. 67:31-38
40. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF. 2006. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 26:1357-63
41. Duez H, Lamarche B, Uffelman KD, Valero R, Szeto L, et al. 2008. Dissociation between the insulinsensitizing effect of rosiglitazone and its effect on hepatic and intestinal lipoprotein production. J. Clin. Endocrinol. Metab. 93:1722-29
42. Duez H, Lamarche B, Valero R, Pavlic M, Proctor S, et al. 2008. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 117:2369-76
43. During A, Dawson HD, Harrison EH. 2005. Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J. Nutr. 135:2305-12
44. Evans K, Kuusela PJ, Cruz ML, Wilhelmova I, Fielding BA, Frayn KN. 1998. Rapid chylomicron appearance following sequential meals: effects of second meal composition. Br. J. Nutr. 79:425-29
45. Farr S, Baker C, Naples M, Taher J, Adeli K. 2014. Central glucagon-like peptide-1 reduces intestinal chylomicron production viamelanocortin-4-receptor signaling. Arterioscler. Thromb. Vasc. Biol. 34(Suppl. 1):A429
46. Federico LM, NaplesM, Taylor D, Adeli K. 2006. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes 55:1316-26
47. Fielding BA, Callow J, Owen RM, Samra JS, Matthews DR, Frayn KN. 1996. Postprandial lipemia: the origin of an early peak studied by specific dietary fatty acid intake during sequential meals. Am. J. Clin. Nutr. 63:36-41
48. Filhoulaud G, Guilmeau S, Dentin R, Girard J, Postic C. 2013. Novel insights into ChREBP regulation and function. Trends Endocrinol. Metab. 24:257-68
49. Gimeno RE, Hirsch DJ, Punreddy S, Sun Y, Ortegon AM, et al. 2003. Targeted deletion of fatty acid transport protein-4 results in early embryonic lethality. J. Biol. Chem. 278:49512-16
50. G ogebakan O, Andres J, Biedasek K, Mai K, Kuhnen P, et al. 2012. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 61:292-300
51. Grant KI, Marais MP, Dhansay MA. 1994. Sucrose in a lipid-rich meal amplifies the postprandial excursion of serum and lipoprotein triglyceride and cholesterol concentrations by decreasing triglyceride clearance. Am. J. Clin. Nutr. 59:853-60
52. Grosskopf I, Ringel Y, Charach G, Maharshak N, Mor R, et al. 1997. Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. Diabetes Care 20:1598-602
53. Guan X, Stoll B, Lu X,Tappenden KA,Holst JJ, et al. 2003. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 125:136-47
54. Haas JT, Winter HS, Lim E, Kirby A, Blumenstiel B, et al. 2012. DGAT1 mutation is linked to a congenital diarrheal disorder. J. Clin. Invest. 122:4680-84
55. Haidari M, Leung N, Mahbub F, Uffelman KD, Kohen-Avramoglu R, et al. 2002. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J. Biol. Chem. 277:31646-55
56. Hampton SM, Morgan LM, Lawrence N, Anastasiadou T, Norris F, et al. 1996. Postprandial hormone and metabolic responses in simulated shift work. J. Endocrinol. 151:259-67
57. Harbis A, Defoort C, Narbonne H, Juhel C, Senft M, et al. 2001. Acute hyperinsulinism modulates plasma apolipoprotein B-48 triglyceride-rich lipoproteins in healthy subjects during the postprandial period. Diabetes 50:462-69
58. Harmel E, Grenier E, Bendjoudi Ouadda A, El Chebly M, Ziv E, et al. 2014.AMPKin the small intestine in normal and pathophysiological conditions. Endocrinology 155:873-88
59. Hayashi H, Fujimoto K, Cardelli JA, Nutting DF, Bergstedt S, Tso P. 1990. Fat feeding increases size, but not number, of chylomicrons produced by small intestine. Am. J. Physiol. 259:G709-19
60. Hazard SE, Patel SB. 2007. Sterolins ABCG5 and ABCG8: regulators of whole body dietary sterols. Pflugers Arch. 453:745-52
61. Hegele RA. 2009. Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet. 10:109-21
62. Hegele RA, Harris SB, Hanley AJ, Sadikian S, Connelly PW, Zinman B. 1996. Genetic variation of intestinal fatty acid-binding protein associated with variation in body mass in aboriginal Canadians. J. Clin. Endocrinol. Metab. 81:4334-37
63. Hein GJ, Baker C, Hsieh J, Farr S, Adeli K. 2012. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes 62:373-81
64. Hogue JC,LamarcheB,DeshaiesY,Tremblay AJ, Bergeron J, et al. 2008. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism 57:246-54
65. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P. 2007. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J. Lipid Res. 48:1336-42
66. Hooper AJ, Robertson K, Barrett PH, Parhofer KG, van Bockxmeer FM, Burnett JR. 2007. Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia. J. Clin. Endocrinol. Metab. 92:1474-78
67. Hsieh J, Longuet C, Baker CL,Qin B, Federico LM, et al. 2010. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53:552-61
68. Hsieh J, Longuet C,Maida A, Bahrami J, Xu E, et al. 2009. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology 137:997-1005
69. Hussain MM, Maxfield FR, Mas-Oliva J, Tabas I, Ji ZS, et al. 1991. Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J. Biol. Chem. 266:13936-40
70. Hussain MM, Pan X. 2015. Circadian regulators of intestinal lipid absorption. J. Lipid Res. 56:761-70
71. Iizuka K, Bruick RK,LiangG,Horton JD, UyedaK. 2004. Deficiency of carbohydrate response elementbinding protein (ChREBP) reduces lipogenesis as well as glycolysis. PNAS 101:7281-86
72. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, et al. 2013. Roux-en-Y gastric bypass versus intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 309:2240-49
73. Iqbal J, Rudel LL, Hussain MM. 2008. Microsomal triglyceride transfer protein enhances cellular cholesteryl esterification by relieving product inhibition. J. Biol. Chem. 283:19967-80
74. Jackson KG, Wolstencroft EJ, Bateman PA, Yaqoob P, Williams CM. 2005. Greater enrichment of triacylglycerol-rich lipoproteins with apolipoproteins E and C-III after meals rich in saturated fatty acids than after meals rich in unsaturated fatty acids. Am. J. Clin. Nutr. 81:25-34
75. James AP, Watts GF, Mamo JC. 2005. The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. Diabetes Obes. Metab. 7:381-89
76. Jeppesen J, Chen YI, Zhou MY, Schaaf P, Coulston A, Reaven GM. 1995. Postprandial triglyceride and retinyl ester responses to oral fat: effects of fructose. Am. J. Clin. Nutr. 61:787-91
77. Johansen CT, Hegele RA. 2012. The complex genetic basis of plasma triglycerides. Curr. Atheroscler. Rep. 14:227-34
78. Jones B, Jones EL, Bonney SA, Patel HN, Mensenkamp AR, et al. 2003. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat. Genet. 34:29-31
79. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. 2014. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 371:32-41
80. Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. 2013. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur. Heart J. 34:1826-33
81. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, et al. 2008. FoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J. Clin. Invest. 118:2347-64
82. Kishore P, Boucai L, Zhang K, Li W, Koppaka S, et al. 2011. Activation of KATP channels suppresses glucose production in humans. J. Clin. Invest. 121:4916-20
83. KooHY, MiyashitaM, Cho BH,NakamuraMT. 2009. Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochem. Biophys. Res. Commun. 390:285-89
84. Lairon D. 2008. Macronutrient intake and modulation on chylomicron production and clearance. Atheroscler. Suppl. 9:45-48
85. Lam TK, Gutierrez-Juarez R, Pocai A, Bhanot S, Tso P, et al. 2007. Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. Nat. Med. 13:171-80
86. Lemieux I, SalomonH,Despres JP. 2003. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels andLDLsize in dyslipidemic patients. Ann. Med. 35:442-48
87. LewisGF, Naples M, Uffelman K, LeungN, Szeto L, Adeli K. 2004. Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting state: studies in insulin-resistant and insulin-sensitized Syrian golden hamsters. Endocrinology 145:5006-12
88. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. 1995. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J. Clin. Invest. 95:158-66
89. Liu L,Wen T, Zheng XY, Yang DG, Zhao SP, et al. 2009. Remnant-like particles accelerate endothelial progenitor cells senescence and induce cellular dysfunction via an oxidative mechanism. Atherosclerosis 202:405-14
90. Mamo JC, James AP, Soares MJ, Griffiths DG, Purcell K, Schwenke JL. 2005. A low-protein diet exacerbates postprandial chylomicron concentration inmoderately dyslipidaemic subjects in comparison to a lean red meat protein-enriched diet. Eur. J. Clin. Nutr. 59:1142-18
91. Mansbach CM, Siddiqi SA. 2010. The biogenesis of chylomicrons. Annu. Rev. Physiol. 72:315-33
92. Masuda D, Hirano K, Oku H, Sandoval JC, Kawase R, et al. 2009. Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J. Lipid Res. 50:999-1011
93. Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, et al. 2006. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49:2049-57
94. Maury E, Ramsey KM, Bass J. 2010. Circadian rhythms and metabolic syndrome: from experimental genetics to human disease. Circ. Res. 106:447-62
95. Meier JJ, Gethmann A, Gotze O, Gallwitz B, Holst JJ, et al. 2006. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 49:452-58
96. Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, et al. 2006. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 130:44-54
97. Mekki N, Charbonnier M, Borel P, Leonardi J, Juhel C, et al. 2002. Butter differs from olive oil and sunflower oil in its effects on postprandial lipemia and triacylglycerol-rich lipoproteins after singlemixed meals in healthy young men. J. Nutr. 132:3642-49
98. Mera Y, Odani N, Kawai T, Hata T, Suzuki M, et al. 2011. Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4-trifluoromethylbiphenyl-2-carbonyl)amino]phenyl}acetyloxymethyl)-2-phenylmalonate ( JTT-130), an intestine-specific inhibitor ofmicrosomal triglyceride transfer protein. J. Pharmacol. Exp. Ther. 336:321-27
99. Milger K, Herrmann T, Becker C, Gotthardt D, Zickwolf J, et al. 2006. Cellular uptake of fatty acids driven by the ER-localized acyl-CoA synthetase FATP4. J. Cell Sci. 119:4678-88
100. MorelE,Demignot S,Chateau D, Chambaz J,RoussetM,Delers F. 2004. Lipid-dependent bidirectional traffic of apolipoprotein B in polarized enterocytes. Mol. Biol. Cell 15:132-41
101. Mortensen LS, Hartvigsen ML, Brader LJ, Astrup A, Schrezenmeir J, et al. 2009. Differential effects of protein quality on postprandial lipemia in response to a fat-rich meal in type 2 diabetes: comparison of whey, casein, gluten, and cod protein. Am. J. Clin. Nutr. 90:41-48
102. Murphy MC, Isherwood SG, Sethi S, Gould BJ, Wright JW, et al. 1995. Postprandial lipid and hormone responses to meals of varying fat contents: modulatory role of lipoprotein lipase? Eur. J. Clin. Nutr. 49:578-88
103. Musunuru K, Pirruccello JP,Do R, PelosoGM, Guiducci C, et al. 2010. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363:2220-27
104. Naples M, Baker C, Lino M, Iqbal J, Hussain MM, Adeli K. 2012. Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 302:G1043-52
105. Nassir F, Wilson B, Han X, Gross RW, Abumrad NA. 2007. CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J. Biol. Chem. 282:19493-501
106. Nauli AM, Nassir F,Zheng S, Yang Q, Lo CM, et al. 2006. CD36 is important for chylomicron formation and secretion and may mediate cholesterol uptake in the proximal intestine. Gastroenterology 131:1197-207
107. Neeli I, Siddiqi SA, Siddiqi S, Mahan J, Lagakos WS, et al. 2007. Liver fatty acid-binding protein initiates budding of pre-chylomicron transport vesicles from intestinal endoplasmic reticulum. J. Biol. Chem. 282:17974-84
108. Newberry EP,Xie Y, Kennedy SM, Luo J, Davidson NO. 2006. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 44:1191-205
109. Niot I, Poirier H, Tran TT, Besnard P. 2009. Intestinal absorption of long-chain fatty acids: evidence and uncertainties. Prog. Lipid Res. 48:101-15
110. Nogueira JP, Maraninchi M, Beliard S, Padilla N, Duvillard L, et al. 2012. Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 32:1039-44
111. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. 2007. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299-308
112. Obici S, Zhang BB, Karkanias G, Rossetti L. 2002. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat. Med. 8:1376-82
113. Ooi EM, Russell BS, Olson E, Sun SZ, Diffenderfer MR, et al. 2012. Apolipoprotein B-100-containing lipoprotein metabolism in subjects with lipoprotein lipase gene mutations. Arterioscler. Thromb. Vasc. Biol. 32:459-66
114. Padilla N, Maraninchi M, Beliard S, Berthet B, Nogueira JP, et al. 2014. Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism in obese, nondiabetic humans. Arterioscler. Thromb. Vasc. Biol. 34:2330-37
115. Pan X, Hussain MM. 2009. Clock is important for food and circadian regulation of macronutrient absorption in mice. J. Lipid Res. 50:1800-13
116. Pan X, Hussain MM. 2012. Gut triglyceride production. Biochim. Biophys. Acta 1821:727-35
117. Pan X, Munshi MK, Iqbal J, Queiroz J, Sirwi AA, et al. 2013. Circadian regulation of intestinal lipid absorption by apolipoprotein AIV involves forkhead transcription factors A2 and O1 and microsomal triglyceride transfer protein. J. Biol. Chem. 288:20464-76
118. Pan X, Zhang Y, Wang L, Hussain MM. 2010. Diurnal regulation of MTP and plasma triglyceride by CLOCK is mediated by SHP. Cell Metab. 12:174-86
119. Parks EJ, Krauss RM, Christiansen MP, Neese RA, Hellerstein MK. 1999. Effects of a low-fat, highcarbohydrate diet on VLDL-triglyceride assembly, production, and clearance. J. Clin. Invest. 104:1087-96
120. Pavlic M, Xiao C, Szeto L, Patterson BW, Lewis GF. 2010. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes 59:580-87
121. Pocai A, Lam TK, Gutierrez-Juarez R, Obici S, Schwartz GJ, et al. 2005. Hypothalamic KATP channels control hepatic glucose production. Nature 434:1026-31
122. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, et al. 2012. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62:1186-95
123. Proctor SD, Mamo JC. 2003. Intimal retention of cholesterol derived from apolipoprotein B100-and apolipoprotein B48-containing lipoproteins in carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler. Thromb. Vasc. Biol. 23:1595-600
124. Qin B, Polansky MM, Sato Y, Adeli K, Anderson RA. 2009. Cinnamon extract inhibits the postprandial overproduction of apolipoprotein B48-containing lipoproteins in fructose-fed animals. J. Nutr. Biochem. 20:901-8
125. Rader DJ, Kastelein JJ. 2014. Lomitapide and mipomersen: two first-in-class drugs for reducing lowdensity lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129:1022-32
126. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, et al. 2011. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478:404-7
127. Repa JJ, Turley SD, Quan G, Dietschy JM. 2005. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J. Lipid Res. 46:779-89
128. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, et al. 2013. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341:1241214
129. Ring A, Le Lay S, Pohl J, Verkade P, StremmelW. 2006. Caveolin-1 is required for fatty acid translocase (FAT/CD36) localization and function at the plasma membrane of mouse embryonic fibroblasts. Biochim. Biophys. Acta 1761:416-23
130. RobertsonMD, Parkes M, Warren BF, Ferguson DJ, JacksonKG, et al. 2003. Mobilisation of enterocyte fat stores by oral glucose in humans. Gut 52:834-39
131. RocheHM, Zampelas A, Jackson KG, Williams CM, Gibney MJ. 1998. The effect of testmealmonounsaturated fatty acid:saturated fatty acid ratio on postprandial lipid metabolism. Br. J. Nutr. 79:419-24
132. Romeo S, Yin W, Kozlitina J, Pennacchio LA, Boerwinkle E, et al. 2009. Rare loss-of-functionmutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119:70-79
133. Sandoval JC,Nakagawa-Toyama Y, Masuda D, Tochino Y,Nakaoka H, et al. 2010. Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice. J. Atheroscler. Thromb. 17:610-18
134. Sane AT, Sinnett D, Delvin E, Bendayan M, Marcil V, et al. 2006. Localization and role of NPC1L1 in cholesterol absorption in human intestine. J. Lipid Res. 47:2112-20
135. Schlierf G, Dorow E. 1973. Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. J. Clin. Invest. 52:732-40
136. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. 2010. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 212:217-22
137. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H. 2008. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol. Sin. 29:698-706
138. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. 2004. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109:1022-28
139. Siddiqi S, Mansbach CM 2nd. 2012. Phosphorylation of Sar1b protein releases liver fatty acid-binding protein from multiprotein complex in intestinal cytosol enabling it to bind to endoplasmic reticulum (ER) and bud the pre-chylomicron transport vesicle. J. Biol. Chem. 287:10178-88
140. Siddiqi S, Sheth A, Patel F, Barnes M, Mansbach CM 2nd. 2013. Intestinal caveolin-1 is important for dietary fatty acid absorption. Biochim. Biophys. Acta 1831:1311-21
141. Siddiqi SA, Mahan J, Siddiqi S, Gorelick FS, Mansbach CM 2nd. 2006. Vesicle-associated membrane protein 7 is expressed in intestinal ER. J. Cell Sci. 119:943-50
142. Siddiqi SA, Siddiqi S, Mahan J, Peggs K, Gorelick FS, Mansbach CM 2nd. 2006. The identification of a novel endoplasmic reticulum to Golgi SNARE complex used by the prechylomicron transport vesicle. J. Biol. Chem. 281:20974-82
143. Sidiropoulos KG,Meshkani R, Avramoglu-Kohen R, Adeli K. 2007. Insulin inhibition of apolipoprotein B mRNA translation is mediated via the PI-3 kinase/mTOR signaling cascade but does not involve internal ribosomal entry site (IRES) initiation. Arch. Biochem. Biophys. 465:380-88
144. Sjostrom L, PeltonenM, Jacobson P, Ahlin S, Andersson-Assarsson J, et al. 2014. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311:2297-304
145. Soh J, Iqbal J, Queiroz J, Fernandez-Hernando C, Hussain MM. 2013. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat. Med. 19:892-900
146. Stahl A, Hirsch DJ, Gimeno RE, Punreddy S, Ge P, et al. 1999. Identification of the major intestinal fatty acid transport protein. Mol. Cell 4:299-308
147. SteinerG, PoapstM,Davidson JK. 1975. Production of chylomicron-like lipoproteins from endogenous lipid by the intestine and liver of diabetic dogs. Diabetes 24:263-71
148. Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold KR, et al. 2004. Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J. Biol. Chem. 279:11767-76
149. Stremmel W. 1988. Uptake of fatty acids by jejunal mucosal cells is mediated by a fatty acid binding membrane protein. J. Clin. Invest. 82:2001-10
150. Tarugi P, Averna M, Di Leo E, Cefalu AB,NotoD, et al. 2007. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis 195:e19-27
151. Timmers S, Konings E, Bilet L, Houtkooper RH, van deWeijer T, et al. 2012. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14:612-22
152. Ting HJ, Stice JP, Schaff UY, Hui DY, Rutledge JC, et al. 2007. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-α. Circ. Res. 100:381-90
153. Tome-Carneiro J, Gonzalvez M, Larrosa M, Garcia-Almagro FJ, Aviles-Plaza F, et al. 2012. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebocontrolled, randomized trial. Mol. Nutr. Food Res. 56:810-21
154. Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. 2011. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes. Metab. 13:366-73
155. Tremblay AJ, Lamarche B, Kelly I, Charest A, Lepine MC, et al. 2014. Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes. Diabetes Obes. Metab. 16:1223-29
156. Tso P, Balint JA. 1986. Formation and transport of chylomicrons by enterocytes to the lymphatics. Am. J. Physiol. 250:G715-26
157. Turnbaugh PJ, Ley RE,Mahowald MA,Magrini V, Mardis ER, Gordon JI. 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027-31
158. Vassileva G, Huwyler L, Poirier K, Agellon LB, Toth MJ. 2000. The intestinal fatty acid binding protein is not essential for dietary fat absorption in mice. FASEB J. 14:2040-46
159. Veilleux A, Grenier E, Marceau P, Carpentier AC, Richard D, Levy E. 2014. Intestinal lipid handling: evidence and implication of insulin signaling abnormalities in human obese subjects. Arterioscler. Thromb. Vasc. Biol. 34:644-53
160. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, et al. 2012. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143:913-16.e7
161. Wang L, Gill R, Pedersen TL,Higgins LJ,Newman JW, Rutledge JC. 2009. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J. Lipid Res. 50:204-13
162. Wasada T, McCorkle K, Harris V, Kawai K, Howard B, Unger RH. 1981. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J. Clin. Invest. 68:1106-7
163. Weinstock PH, Bisgaier CL, Hayek T, Aalto-Setala K, Sehayek E, et al. 1997. Decreased HDL cholesterol levels but normal lipid absorption, growth, and feeding behavior in apolipoprotein A-IV knockout mice. J. Lipid Res. 38:1782-94
164. WeintraubMS, Zechner R, Brown A, Eisenberg S, Breslow JL. 1988. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J. Clin. Invest. 82:1884-93
165. Westphal S, Kastner S, Taneva E, Leodolter A, Dierkes J, Luley C. 2004. Postprandial lipid and carbohydrate responses after the ingestion of a casein-enriched mixed meal. Am. J. Clin. Nutr. 80:284-90
166. Westphal S, Leodolter A, Kahl S, Dierkes J, Malfertheiner P, Luley C. 2002. Addition of glucose to a fatty meal delays chylomicrons and suppresses VLDL in healthy subjects. Eur. J. Clin. Invest. 32:322-27
167. Willnow TE. 1997. Mechanisms of hepatic chylomicron remnant clearance. Diabetic Med. 14(Suppl. 3):S75-80
168. Wong AT, Chan DC, Barrett PH, Adams LA,Watts GF. 2014. Effect of omega-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. J. Clin. Endocrinol. Metab. 99:E1427-35
169. Xiao C, Bandsma RH, Dash S, Szeto L, Lewis GF. 2012. Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Arterioscler. Thromb. Vasc. Biol. 32:1513-19
170. Xiao C, Dash S, Lewis GF. 2012. Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system. Cardiovasc. Hematol. Agents Med. Chem. 10:289-94
171. Xiao C, Dash S, Morgantini C, Lewis GF. 2013. Novel role of enteral monosaccharides in intestinal lipoprotein production in healthy humans. Arterioscler. Thromb. Vasc. Biol. 33:1056-62
172. Xiao C, Dash S, Morgantini C, Patterson BW, Lewis GF. 2014. Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans. Diabetes 63:2394-401
173. Xiao C, Hsieh J, Adeli K, Lewis GF. 2011. Gut-liver interaction in triglyceride-rich lipoprotein metabolism. Am. J. Physiol. Endocrinol. Metab. 301:E429-46
174. Xiao C, Lewis GF. 2012. Regulation of chylomicron production in humans. Biochim. Biophys. Acta 1821:736-46
175. Yang LY, Kuksis A. 1991. Apparent convergence (at 2-monoacylglycerol level) of phosphatidic acid and 2-monoacylglycerol pathways of synthesis of chylomicron triacylglycerols. J. Lipid Res. 32:1173-86
176. Yen CL, Cheong ML, Grueter C, Zhou P, Moriwaki J, et al. 2009. Deficiency of the intestinal enzyme acylCoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding. Nat. Med. 15:442-46
177. Yen CL, Farese RV Jr. 2003. MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine. J. Biol. Chem. 278:18532-37
178. Yue JT, Mighiu PI, Naples M, Adeli K, Lam TK. 2012. Glycine normalizes hepatic triglyceride-rich VLDL secretion by triggering the CNS in high-fat fed rats. Circ. Res. 110:1345-54